Tag: FDA approvals

The essentials: On July 9 to 10, 2026, the FDA approved Sarclisa Escena (isatuximab-irfc, Sanofi-Aventis) for subcutaneous injection across all currently approved multiple myeloma indications for IV Sarclisa. Sarclisa Escena is the same isatuximab molecule as IV Sarclisa, delivered subcutaneously rather than intravenously. It is the first anticancer treatment approved for administration via an on-body injector (OBI). The approved indications (matching existing IV Sarclisa indications): in combination with pomalidomide and dexamethasone (Pd) for adults with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor; in combination with carfilzomib and dexamethasone (Kd) for adults with relapsed or refractory multiple myeloma after 1 to 3 prior lines of therapy; in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation. Administration: 1,400 mg fixed dose subcutaneous injection using the CirCLIQ on-body delivery system (OBDS) made by Enable Injections, or manual subcutaneous injection with a syringe and infusion set. The OBI is a wearable device with a concealed, retractable 30-gauge needle that delivers the drug hands-free via low-pressure interstitial flow. No hyaluronidase required. Weight-independent flat dosing replaces the weight-based IV dosing (10 mg/kg). The clinical basis: Phase 3 IRAKLIA (NCT05405166), 531 patients randomized 1:1 to subcutaneous OBI isatuximab plus Pd or IV isatuximab plus Pd. Published in Journal of Clinical Oncology. Co-primary endpoints: ORR and steady-state trough concentration. ORR 71.1% (SC-OBI) versus 70.5% (IV); relative risk 1.008 (95% CI 0.903 to 1.126); p=0.0006, meeting non-inferiority. Mean trough Ctrough at cycle 6 day 1: 499 μg/mL (SC-OBI) versus 340 μg/mL (IV); geometric mean ratio 1.532 (90% CI 1.316 to 1.784), also non-inferior and in fact higher with SC. Systemic infusion reactions: 1.5% (SC-OBI) versus 25.0% (IV). Injection site reactions: 0.4% of all OBI injections, all grade 1 or 2. 99.9% of injections completed without interruption. Patient satisfaction: 70% satisfied or very satisfied with SC-OBI versus 53.4% with IV (OR 2.036; 95% CI 1.425 to 2.908; p=0.0001). Additional supporting studies: IZALCO (NCT05704049, Phase 2, Kd combination); IsaSocut/ISASCOUT (NCT05889221, Phase 2, VRd combination, transplant-ineligible NDMM). European Commission approved Sarclisa Escena on June 8, 2026, across all indications.

Multiple myeloma is a cancer that requires years of treatment. Not months. Years. Patients who achieve remission on first-line therapy eventually relapse and begin second-line treatment. Then third-line. Then fourth. The treatment calendar for a myeloma patient who responds well can span a decade or more of clinic visits, drug combinations, and ongoing monitoring. During that time, every hour spent sitting in an infusion chair is an hour that is not spent at work, with family, or simply living without the constant reminder that cancer still defines the schedule.

Anti-CD38 antibodies, which include daratumumab (Darzalex) and isatuximab (Sarclisa), are among the most effective drugs in the myeloma armamentarium. They are also, in their intravenous form, among the most time-intensive. The first IV infusion of an anti-CD38 antibody typically takes 4 to 6 hours due to pre-medication requirements and slow infusion rates to manage infusion reactions. Subsequent infusions are faster but still take 1 to 3 hours. For a drug given weekly in cycle 1 and then every 2 weeks for relapsed disease, this adds up quickly.

Daratumumab solved this with its subcutaneous formulation Darzalex Faspro, approved in 2020, which uses hyaluronidase to deliver the drug subcutaneously in a few minutes. Sarclisa Escena, approved July 9, 2026, solves the same problem for isatuximab, but takes the approach in a genuinely novel direction: it is the first anticancer drug in history approved for delivery via an on-body injector, a wearable device that administers the injection hands-free without the patient needing to hold a syringe, without requiring hyaluronidase, and with a concealed retractable needle that eliminates needle-stick risk for both patient and provider.

The Phase 3 IRAKLIA trial showed that the SC-OBI approach is not merely convenient. It is clinically equivalent to IV isatuximab on every meaningful efficacy measure, produces higher steady-state drug concentrations, and reduces systemic infusion reactions from 25% with IV to 1.5% with the on-body approach.

---

What Multiple Myeloma Is and Why CD38 Is Such an Important Target

Multiple myeloma is a cancer of plasma cells, the antibody-producing cells of the immune system that reside in the bone marrow. In myeloma, malignant plasma cells proliferate uncontrollably, crowd out normal blood cell production, and produce large quantities of a dysfunctional monoclonal protein (M-protein) that serves as a disease biomarker but can also damage the kidneys. The resulting clinical picture includes anemia, bone lesions, kidney damage, immunosuppression, and hypercalcemia.

Multiple myeloma is the second most common blood cancer in the United States, with approximately 36,000 new diagnoses and 12,000 deaths annually. It remains incurable for most patients, though effective modern treatments have extended median survival from approximately 3 years in the 1990s to 6 to 8 years or more for many patients today. Patients cycle through treatment regimens, entering remission, eventually relapsing, and then requiring a new regimen that typically includes drugs from different mechanistic classes.

CD38 is a transmembrane glycoprotein expressed at very high levels on myeloma plasma cells, making it an ideal therapeutic target. CD38 is expressed on normal lymphoid and myeloid cells as well, but at much lower levels than on myeloma cells, providing a therapeutic window for anti-CD38 antibodies to selectively target the malignant population.

Anti-CD38 antibodies kill myeloma cells through multiple mechanisms: antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct apoptosis induction. They also deplete immunosuppressive CD38-positive regulatory T cells and regulatory B cells, which may additionally improve the anti-tumor immune response. This multi-mechanism killing is one reason CD38-directed antibodies are effective even in heavily pretreated myeloma and why they have become a backbone of therapy across multiple lines of treatment.

---

What Isatuximab Is and How Sarclisa Escena Relates to IV Sarclisa

Isatuximab (Sarclisa) is a CD38-directed IgG1 monoclonal antibody that differs from daratumumab in the specific epitope on CD38 it binds and in its mechanism of triggering apoptosis (daratumumab requires cross-linking for apoptotic signaling; isatuximab induces apoptosis through receptor clustering independent of cross-linking). In clinical practice, both are effective CD38-targeting antibodies used in complementary regimens in the myeloma treatment landscape.

IV Sarclisa was approved by the FDA in:

• March 2020 for relapsed/refractory myeloma in combination with pomalidomide and dexamethasone (ICARIA-MM trial)
• March 2021 in combination with carfilzomib and dexamethasone (IKEMA trial)
• March 2024 in combination with VRd for transplant-ineligible newly diagnosed myeloma (IMROZ trial)

Sarclisa Escena is not a new drug. It is the same isatuximab-irfc molecule delivered by a different route. The “Escena” suffix distinguishes the subcutaneous formulation from the IV formulation for prescribing, dispensing, and packaging purposes. All three indications approved for IV Sarclisa are now equally approved for Sarclisa Escena SC, with the same combination regimen partners and the same patient eligibility criteria.

The dose change is meaningful: IV isatuximab is dosed at 10 mg/kg, meaning the volume infused varies by patient weight. Sarclisa Escena uses a fixed flat dose of 1,400 mg regardless of patient weight. This simplifies preparation and administration, reduces the potential for weight-based dosing errors, and enables the on-body injector to deliver a predetermined fixed volume to every patient.

---

The CirCLIQ On-Body Delivery System: What It Is and How It Works

The CirCLIQ on-body delivery system (OBDS), manufactured by Enable Injections of Cincinnati, Ohio, is the central innovation of the Sarclisa Escena approval. Understanding what it does requires understanding why subcutaneous delivery of large-volume biologics has historically required either hyaluronidase or a slow infusion.

The subcutaneous space has limited capacity. Subcutaneous tissues resist high-pressure injection of large volumes because the dense extracellular matrix of hyaluronan and collagen creates physical resistance. Conventional subcutaneous injections of most drugs deliver volumes under 1 to 2 mL. Biologics like anti-CD38 antibodies at therapeutic doses require much larger volumes.

There are two established solutions. Hyaluronidase (used in Darzalex Faspro and Keytruda Qlex) temporarily breaks down the hyaluronan matrix, allowing larger volumes to be injected rapidly by dispersing through the loosened tissue. The CirCLIQ approach takes a different path: it uses low-pressure, interstitial-rate delivery, meaning it delivers the drug slowly enough that the subcutaneous tissue can accommodate the volume without requiring enzymatic disruption of the matrix.

Concretely, the CirCLIQ device:

• Is worn on the body surface (typically the abdomen) and attached by the patient or healthcare provider before administration begins
• Contains a single-use, concealed, retractable 30-gauge needle that inserts automatically when activated, eliminating visible needle exposure and reducing sharps anxiety for needle-phobic patients
• Delivers the drug hands-free once activated, freeing the patient and provider from holding a syringe during the infusion period
• Uses flow rates calibrated to the patient’s interstitial pressure rather than a fixed pump rate, individualized delivery based on how the specific tissue responds
• Does not require hyaluronidase as a co-formulation or co-injection
• Completes drug delivery in approximately 7 to 9 minutes per the IRAKLIA experience, far shorter than IV infusions but longer than the 1 to 2 minutes for Keytruda Qlex’s conventional SC injection

A critical safety feature: the needle retracts automatically after injection completion, preventing accidental needle-stick injuries. In IRAKLIA, 99.9% of all OBI injections (5,145 total injections analyzed) completed without interruption, demonstrating exceptional mechanical reliability across a large real-world operational dataset.

For oncology practices, this also means nursing workload is different. Rather than manually maintaining an IV line and titrating infusion rates through an infusion pump, a nurse or medical assistant attaches the OBI device and activates it. The patient then waits, wearing the device, until delivery completes. The hands-free nature means nursing attention can be allocated elsewhere during the delivery period.

---

The IRAKLIA Trial: Full Data

Design

IRAKLIA (NCT05405166) was an international, multicenter, open-label, randomized, Phase 3 non-inferiority trial. It enrolled 531 adults (age 18 or older) with relapsed/refractory multiple myeloma who had received at least one prior line of therapy. Patients were randomized 1:1 to:

• Sarclisa Escena 1,400 mg SC via CirCLIQ OBI plus pomalidomide plus dexamethasone (n=263)
• IV isatuximab 10 mg/kg plus pomalidomide plus dexamethasone (n=268)

Both arms received isatuximab weekly in cycle 1, then every 2 weeks. Pomalidomide 4 mg daily on days 1 to 21 and dexamethasone 40 mg weekly (20 mg for patients aged 75 or older) were the standard partner regimen.

Co-primary endpoints were ORR (by Independent Review Committee using 2016 IMWG criteria) and isatuximab trough plasma concentration at steady state (Ctrough at cycle 6, day 1 predose). Non-inferiority was declared if both primary endpoints met their prespecified non-inferiority margins. The trial was published in the Journal of Clinical Oncology (JCO) with a 12-month median follow-up.

Efficacy results

Endpoint	SC-OBI isatuximab (n=263)	IV isatuximab (n=268)	Result
ORR (co-primary)	71.1%	70.5%	Relative risk 1.008 (95% CI 0.903 to 1.126); p=0.0006; non-inferior
Mean Ctrough at C6D1 (co-primary)	499 μg/mL (SD 259)	340 μg/mL (SD 169)	Geometric mean ratio 1.532 (90% CI 1.316 to 1.784); non-inferior
VGPR or better rate	Similar between arms	Similar between arms	Comparable depth of response
Patient satisfaction (satisfied or very satisfied)	70%	53.4%	OR 2.036 (95% CI 1.425 to 2.908); p=0.0001
Median follow-up	12 months	12 months	—

Source: Richardson PG et al. IRAKLIA: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pd in R/R MM. JCO. 2025. doi:10.1200/JCO-25-00744. NCT05405166.

The ORR non-inferiority result is the core efficacy finding: 71.1% versus 70.5%, a difference of 0.6 percentage points in a trial that randomized 531 patients, establishes that the SC-OBI route delivers identical anti-tumor activity to IV administration. The non-inferiority margin was met with high statistical confidence (p=0.0006).

The Ctrough finding is particularly notable: the SC route actually achieved a higher mean steady-state trough concentration (499 μg/mL) than the IV route (340 μg/mL). This is not a paradox. With subcutaneous administration, drug is absorbed gradually from the subcutaneous depot over time, producing a flatter pharmacokinetic curve with higher trough levels compared to the sharp peak and faster decline seen with IV infusion. Higher troughs are generally associated with better sustained target coverage and may contribute to at least comparable or potentially superior outcomes with the SC formulation over longer follow-up periods.

The patient satisfaction finding (70% satisfied or very satisfied with SC-OBI versus 53.4% with IV, p=0.0001) is a patient-reported outcome that the trial was specifically designed to capture and the FDA considered in its evaluation. A statistically significant, nearly 17-percentage-point improvement in patient satisfaction with the same clinical efficacy is a meaningful clinical finding, not a marketing data point.

Safety results

Safety item	SC-OBI	IV	Clinical relevance
Systemic infusion-related reactions	1.5%	25.0%	Dramatic reduction; one of the most important safety differences
Local injection site reactions	0.4% of injections (all grade 1 or 2)	—	Rare, mild, and self-limiting
Grade 3 or higher treatment-emergent adverse events	81.7%	76.1%	Numerically higher with SC; reflects complex relapsed/refractory myeloma population; no unexpected signals
Treatment discontinuation due to injection reactions	0	Not reported	No discontinuations from injection site events with SC
Injections completed without interruption	99.9% (5,144 of 5,145)	—	Exceptional device reliability

Source: JCO IRAKLIA publication; Applied Clinical Trials Online IRAKLIA/IZALCO data summary.

The infusion reaction reduction from 25% to 1.5% is the most clinically impactful safety finding. Infusion-related reactions (IRRs) with IV anti-CD38 antibodies are a well-established class effect: daratumumab and isatuximab both require premedication with antihistamines, corticosteroids, and antipyretics before each IV infusion, and the first infusion is typically given slowly over 4 to 6 hours precisely because of IRR risk. These reactions, while usually manageable, add time, require nursing monitoring, and occasionally require interruption or rate adjustment. Some patients experience reactions severe enough to require treatment delays.

The 1.5% systemic reaction rate with SC-OBI means the premedication burden and the nursing monitoring for systemic reactions are dramatically reduced, not eliminated but reduced to an extent that meaningfully changes the clinical experience of receiving isatuximab.

The numerically higher grade 3 or higher TEAE rate with SC (81.7% versus 76.1%) reflects the overall adverse event burden of treating relapsed/refractory myeloma rather than a SC-specific safety concern. These events are consistent with the established IV isatuximab safety profile and reflect the toxicity of the full triplet regimen (isatuximab plus pomalidomide plus dexamethasone) in a population who has already received multiple prior therapies.

Supporting studies: IZALCO and ISASCOUT

Beyond IRAKLIA, the FDA’s approval across all three indications was further supported by:

IZALCO (NCT05704049): Phase 2 study evaluating SC isatuximab via OBI in combination with carfilzomib and dexamethasone (Kd) in relapsed/refractory myeloma. In IZALCO, approximately 75% of patients preferred the OBI approach over manual subcutaneous injection, with high efficacy and minimal injection site reactions, providing patient preference data for the Kd combination regimen.

IsaSocut/ISASCOUT (NCT05889221): Phase 2 study evaluating SC isatuximab in combination with VRd in transplant-ineligible newly diagnosed myeloma, providing supportive data for the NDMM indication.

---

Sarclisa Escena’s Complete Indication Coverage

Indication	Partners	Patient population	Approval basis
Relapsed/refractory MM, at least 1 prior line including lenalidomide and a PI	Pomalidomide plus dexamethasone (Pd)	Adults	IRAKLIA Phase 3 (primary pivotal)
Relapsed/refractory MM, 1 to 3 prior lines	Carfilzomib plus dexamethasone (Kd)	Adults	IZALCO Phase 2 plus IV IKEMA extrapolation
Newly diagnosed MM, transplant-ineligible	Bortezomib plus lenalidomide plus dexamethasone (VRd)	Adults	ISASCOUT Phase 2 plus IV IMROZ extrapolation

---

Safety: What the Full Prescribing Information Covers

The safety profile of Sarclisa Escena follows the established profile of IV isatuximab with the key modification of substantially reduced systemic infusion reactions and the addition of local injection site reaction monitoring.

Warnings and precautions from the Sarclisa Escena prescribing information:

Hypersensitivity and administration reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported with isatuximab. For SC administration, systemic reactions occur at a dramatically lower rate than with IV (1.5% versus 25% in IRAKLIA), but monitoring for hypersensitivity remains required. Premedication with corticosteroids, antihistamines, and antipyretics is still recommended before administration, though the required observation period post-administration may differ from IV protocols. Clinicians should follow the Sarclisa Escena prescribing information specifically for SC premedication and monitoring guidance.

Neutropenia: Neutropenia is one of the most common and serious adverse events with isatuximab-containing regimens. Grade 3 or higher neutropenia is expected in a substantial proportion of patients, particularly when combined with pomalidomide. CBC monitoring before each cycle is standard. G-CSF support may be required. Dose modifications for neutropenia follow the regimen-specific guidance in the prescribing information.

Infections: Isatuximab causes immunosuppression through depletion of CD38-positive immune cells. Serious infections including pneumonia, upper respiratory tract infections, and opportunistic infections have been reported. Prophylactic antimicrobial coverage consistent with institutional protocols for myeloma regimens should be considered.

Secondary primary malignancies: As with other myeloma regimens involving immunomodulatory drugs (IMiDs), secondary primary malignancies have been reported. Routine monitoring is recommended.

Laboratory test interference: Isatuximab, as an IgG kappa monoclonal antibody, may be detected by serum protein electrophoresis and immunofixation assays used to monitor M-protein, potentially interfering with disease response assessment. This is a known class effect of anti-CD38 antibodies, and the prescribing information addresses how to distinguish isatuximab signal from M-protein response.

Embryo-fetal toxicity: Isatuximab can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for 5 months after the last dose. Males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the last dose.

---

What This Means for Patients and Oncology Practices

For patients

For a patient with relapsed myeloma starting isatuximab-Pd in the second or later line, Sarclisa Escena offers the same clinical activity as IV Sarclisa with three meaningful practical advantages: substantially fewer systemic infusion reactions (1.5% versus 25%), no IV line required, and a device-based administration that eliminates the need to sit connected to an IV drip for an extended period.

The administration time with the OBI, approximately 7 to 9 minutes for the drug delivery itself plus setup and monitoring time, is not as fast as a 1- to 2-minute SC push injection. But it is substantially shorter than a 1- to 3-hour IV infusion on subsequent cycles, and the fact that it is hands-free changes the character of the clinical visit. The patient wears the device and waits; the nurse does not need to maintain a drip line throughout.

For patients receiving isatuximab as part of the VRd regimen for newly diagnosed transplant-ineligible disease, where therapy may continue for years, the cumulative reduction in infusion chair time and in systemic IRR events is substantial over a full treatment course.

The question of whether home administration of Sarclisa Escena is possible in the future is a natural one given the on-body injector format. The current approval specifies administration with a healthcare provider present. Sanofi has indicated that home administration is a future potential that the technology enables, but it is not part of the current label or commercial rollout.

For oncology practices

The CirCLIQ OBI changes the nursing workflow for isatuximab administration in ways that vary by practice setting. Setup, patient education on wearing the device, and post-administration monitoring remain required. But the hands-free delivery frees nursing time during the actual drug administration period compared to IV management. For infusion centers operating at capacity with long chair times, the shift from 1 to 3 hours of IV infusion to a shorter SC OBI session could increase throughput.

The absence of hyaluronidase in the Sarclisa Escena formulation is also a practical supply chain point: no separate co-formulation is required, and the flat 1,400 mg dose eliminates weight-based calculation and the preparation variability that comes with it.

As Dr. Mohamad Mohty, Professor of Hematology at Sorbonne University and Head of Clinical Hematology and Cellular Therapy at Saint-Antoine Hospital in Paris, noted: “The ability to administer a therapy through an on-body injector, particularly an anti-CD38 monoclonal antibody with well-established efficacy, either in the clinic or at home, represents a meaningful step forward.”

For related HED coverage on multiple myeloma therapeutics, see our posts on Pomalyst (pomalidomide) losing exclusivity and what generic pomalidomide means for myeloma access in the 2026 LOE series, and on the Tregzi (marnetegragene autotemcel) approval for allogeneic stem cell transplantation in blood cancers.

For patients and families navigating a multiple myeloma diagnosis, the Multiple Myeloma Research Foundation (themmrf.org; 1-888-841-6673) and the International Myeloma Foundation (myeloma.org; 1-800-452-CURE) maintain current patient resources, treatment information, and clinical trial directories.

---

Sources

FDA approval announcement: FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications. FDA.gov. July 9, 2026.

Sanofi FDA approval press release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector. GlobeNewswire. July 10, 2026.

Drugs.com approval news: FDA Approves Sarclisa Escena (isatuximab-irfc) Subcutaneous Injection for the Treatment of Multiple Myeloma. drugs.com. July 10, 2026.

IRAKLIA primary JCO publication: Richardson PG et al. Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study. Journal of Clinical Oncology. 2025. doi:10.1200/JCO-25-00744.

IRAKLIA trial registration: NCT05405166. ClinicalTrials.gov.

ASCO Post clinical summary: FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications. ascopost.com. July 2026.

OncLive (OBI mechanism, safety data, IZALCO preference data): FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma. onclive.com. July 2026.

CancerNetwork (patient satisfaction OR data): FDA Approves Subcutaneous Isatuximab in Multiple Myeloma. cancernetwork.com. July 2026.

Targeted Oncology (full indications and supporting studies): FDA Approves Subcutaneous Isatuximab for Multiple Myeloma. targetedonc.com. July 2026.

PharmExec (CirCLIQ mechanism detail and competitive context): FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma. pharmexec.com. July 2026.

BioPharm International (IRAKLIA full data table, EC approval context): EC Approves Sanofi’s Subcutaneous Isatuximab for Multiple Myeloma Across All Existing Indications. biopharminternational.com. June 2026.

Applied Clinical Trials (IRAKLIA/IZALCO combined data summary): Phase III IRAKLIA and Phase II IZALCO Trials Support Sarclisa On-Body Delivery. appliedclinicaltrialsonline.com. October 2025.

International Myeloma Foundation approval news: Subcutaneous Sarclisa (isatuximab-irfc) FDA Approved for Myeloma. myeloma.org. July 2026.

OncoDaily clinical overview: FDA Approved Subcutaneous Isatuximab: Advancing Anti-CD38 Therapy Delivery in Multiple Myeloma. oncodaily.com. July 2026.

ASH 2025 body weight PK sub-analysis: Isatuximab Subcutaneous by On-Body Injector in R/R MM: Effect of Body Weight on Pharmacokinetics. Blood. 2025;146(Supplement 1):5812.

IZALCO trial registration: NCT05704049. ClinicalTrials.gov.

ISASCOUT trial registration: NCT05889221. ClinicalTrials.gov.

IV Sarclisa original FDA approval: FDA approves isatuximab-irfc for multiple myeloma. FDA.gov.

CD38 biology: CD38 in Multiple Myeloma. PMC7734386.

Multiple myeloma overview: Multiple Myeloma. StatPearls. NCBI.

Sarclisa Escena prescribing information: SARCLISA ESCENA (isatuximab-irfc) Prescribing Information. Sanofi-Aventis. 2026.

Sarclisa Escena approval history: Sarclisa Escena FDA Approval History. drugs.com.

Enable Injections (CirCLIQ manufacturer): Enable Injections. enableinjections.com.

Patient resources: Multiple Myeloma Research Foundation: 1-888-841-6673 | International Myeloma Foundation: 1-800-452-CURE | Leukemia and Lymphoma Society | Sanofi Sarclisa patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Sarclisa Escena (isatuximab-irfc) is approved for subcutaneous administration and currently requires administration with a healthcare provider present. Treatment decisions for multiple myeloma, including regimen selection and the choice between IV Sarclisa and Sarclisa Escena SC, should be made in close collaboration with a board-certified hematologist or medical oncologist experienced in myeloma management.

The essentials: On June 26, 2026, the FDA approved Lumvoa (veligrotug-vvze, Viridian Therapeutics) for the treatment of thyroid eye disease (TED) in adults. Lumvoa is the second FDA-approved pharmacologic therapy for TED, following teprotumumab (Tepezza, Amgen/Horizon), which was approved in 2020 for active TED. What makes Lumvoa distinct: it is the first FDA-approved treatment for TED with labeling that includes clinical data in both active and chronic TED, making it the first therapy with a regulatory basis for use across the full disease spectrum. Mechanism: veligrotug is a full antagonist of the insulin-like growth factor-1 receptor (IGF-1R), a humanized monoclonal antibody that completely blocks IGF-1R signaling. This distinguishes it from teprotumumab, which is a partial/mixed agonist-antagonist. Regulatory designations: Breakthrough Therapy Designation; Priority Review. Clinical basis: Phase 3 THRIVE (NCT05176639) in active TED and Phase 3 THRIVE-2 (NCT06021054) in chronic TED. Both trials met their primary endpoint and all secondary endpoints at week 15 with high statistical significance. THRIVE (active TED, n=113): Proptosis Responder Rate (PRR) 70% versus 5% placebo (p less than 0.0001); mean proptosis reduction 2.9 mm versus 0.5 mm; diplopia complete resolution 54% versus 12% (p less than 0.0001). THRIVE-2 (chronic TED, n=188): PRR 56% versus 8% (p less than 0.0001); mean proptosis reduction 2.34 mm versus 0.46 mm; diplopia improvement 56% versus 25% (p=0.0006); diplopia complete resolution 32% versus 14% (p=0.0152). Rapid onset: statistically significant proptosis reduction observed as early as week 3 (after one infusion) in both trials. Treatment course: 5 intravenous infusions administered every 3 weeks (infusions at weeks 0, 3, 6, 9, 12; primary analysis at week 15). Shorter infusion course than teprotumumab (8 infusions). Key safety: infusion reactions approximately 9%; hyperglycemia 12% including patients without pre-existing diabetes; hearing impairment (class risk); muscle spasms most common adverse reaction. Available now: commercial launch immediately following approval.

Thyroid eye disease is one of those conditions that sounds manageable until you understand what it actually does to the people who have it. The immune system targets the tissues behind and around the eye — the orbital fat, the extraocular muscles, the connective tissue. The result can include forward protrusion of the eyeball (proptosis) that makes it impossible to close the eye fully, double vision that prevents driving or reading or functioning normally, and pain behind the eyes that is present with every eye movement. At its most severe, the expansion of orbital tissue compresses the optic nerve, threatening permanent vision loss.

Before 2020, the only systemic treatment for TED was intravenous corticosteroids, which reduce inflammation but do not address the underlying disease mechanism. In 2020, teprotumumab (Tepezza) became the first drug approved specifically for TED, targeting the insulin-like growth factor-1 receptor (IGF-1R) and demonstrating that the proptosis and diplopia of TED could be substantially reversed pharmacologically.

Lumvoa (veligrotug-vvze, Viridian Therapeutics), approved June 26, 2026, is the second drug approved for TED — and the first with regulatory labeling that includes data across the full disease spectrum, both active and chronic phases. The THRIVE and THRIVE-2 Phase 3 trials demonstrated not only that veligrotug works in both phases, but that it works rapidly, producing statistically significant proptosis reduction after just one infusion in week 3, with diplopia improvements that are among the most robust data ever generated for any TED therapy.

---

What Thyroid Eye Disease Is and Why the Active/Chronic Distinction Matters

Thyroid eye disease is a rare autoimmune orbitopathy most commonly associated with Graves disease, a condition in which autoantibodies against the thyroid-stimulating hormone receptor (TSHR) drive overproduction of thyroid hormone. In TED, those same autoantibodies, along with antibodies to IGF-1R, activate fibroblasts in the orbital fat and extraocular muscles, triggering inflammation, glycosaminoglycan accumulation, and remodeling of the orbital soft tissues. The result is a progressive expansion of orbital volume that pushes the eyeball forward (proptosis) and impairs the function of the muscles that move it (causing diplopia and limiting motility).

TED affects approximately 16 to 19 adults per 100,000, primarily those with Graves disease, though it can occur in euthyroid or hypothyroid patients with autoimmune thyroid conditions. Women are more commonly affected than men.

The active and chronic phases: why they are clinically distinct

Disease phase	Definition	Characteristics	Clinical significance
Active TED	Clinical Activity Score (CAS) at or above 3/7; onset within approximately 15 months	Active inflammation; edema; periorbital redness; pain; rapidly changing proptosis	Amenable to anti-inflammatory intervention; spontaneous partial remission possible
Chronic TED	CAS below 3; disease onset more than 15 months ago	Fibrosis and remodeling dominate over active inflammation; proptosis is stable; diplopia is fixed	Less responsive to corticosteroids; fibrotic changes once thought irreversible; surgical intervention (orbital decompression, strabismus surgery, eyelid surgery) traditionally the primary option

This distinction has historically defined treatment options. Teprotumumab’s pivotal trial was conducted in active TED, and its label is primarily supported by data in this phase. Patients with chronic TED, who have passed through the active inflammatory phase into a state dominated by fibrotic orbital remodeling, have had essentially no systemic pharmacologic options except orbital decompression surgery.

The THRIVE-2 trial, conducted specifically in chronic TED, is the first global Phase 3 randomized controlled trial to demonstrate statistically significant improvement in both proptosis and diplopia in this population. That is the clinical significance of Lumvoa’s “both active and chronic” labeling.

---

The Science: Why IGF-1R Is the Target and What “Full Antagonist” Means

The IGF-1R/TSHR cross-talk mechanism

The pathogenesis of TED involves a synergistic interaction between two surface receptors on orbital fibroblasts: the thyroid-stimulating hormone receptor (TSHR) and the insulin-like growth factor-1 receptor (IGF-1R). These two receptors form a physical complex on the fibroblast surface and engage in molecular cross-talk: activation of one sensitizes or amplifies signaling through the other.

In TED, autoantibodies against TSHR and IGF-1R activate this fibroblast complex, driving: expansion of orbital preadipocytes into mature fat cells (hyaluronan-producing adipogenesis); differentiation of fibroblasts into myofibroblasts that produce the fibrous connective tissue that hardens the orbital fat; and production of hyaluronic acid and glycosaminoglycans that attract water, expanding orbital volume further. The combination of fat expansion, glycosaminoglycan accumulation, and fibrotic remodeling produces the characteristic proptosis, restricted ocular motility, and diplopia of TED.

IGF-1R inhibition interrupts this fibroblast activation cascade at the receptor level. By blocking IGF-1R, the downstream signaling pathways (PI3K/Akt, MAPK/ERK) that drive fibroblast proliferation, differentiation, and hyaluronan synthesis are suppressed. The anti-inflammatory effect follows: the cycle of immune cell recruitment driven by fibroblast activation slows, and the structural remodeling that produces proptosis is interrupted.

Full antagonist versus partial agonist-antagonist: the distinction from teprotumumab

Veligrotug is described as a full antagonist of IGF-1R. This is a specific pharmacological claim that distinguishes it from teprotumumab.

Teprotumumab acts as a partial agonist at IGF-1R in certain contexts: while it blocks much of IGF-1R’s downstream signaling, it also produces some residual IGF-1R activation through the receptor before its internalization and degradation. Veligrotug, by contrast, binds the receptor and completely blocks signaling without producing any agonist activation. The clinical relevance of this pharmacological distinction is an active area of investigation, but the theoretical benefit of full antagonism is the absence of any compensatory receptor activation that might limit or counterbalance the therapeutic blockade.

The “full antagonist” distinction is included in Lumvoa’s approved labeling, which is clinically notable. It is not a marketing description; it is a regulatory characterization of the drug’s pharmacological mechanism supported by preclinical and clinical evidence provided to the FDA.

---

The THRIVE and THRIVE-2 Trials: Complete Data

THRIVE: Phase 3 in active TED

THRIVE (NCT05176639) was a randomized, double-masked, placebo-controlled Phase 3 trial enrolling adults with moderate-to-severe active TED, defined by CAS at or above 3/7, proptosis at or above 3 mm, and disease onset within 15 months of screening.

Patients were randomized to veligrotug 10 mg/kg IV or placebo, administered every 3 weeks for 5 total infusions (at weeks 0, 3, 6, 9, and 12), with the primary analysis at week 15. The trial enrolled 113 patients (75 veligrotug; 38 placebo).

Endpoint at week 15	Veligrotug	Placebo	p-value
Proptosis Responder Rate (PRR by Hertel)	70%	5%	p less than 0.0001
PRR by MRI/CT	69%	9%	p less than 0.0001
Mean proptosis reduction	2.9 mm	0.5 mm	p less than 0.0001
Mean CAS reduction	3.4 points	1.7 points	p less than 0.0001
Diplopia complete resolution (in patients with diplopia at baseline)	54% (27/50)	12% (3/26)	p less than 0.0001
PRR statistically significant from week 3 (after 1 infusion)	Yes	—	p less than 0.0001

Source: Endocrine Practice THRIVE topline results abstract. 2025. PMC12545473. THRIVE NCT05176639.

The 70% proptosis responder rate at week 15 — compared to 5% for placebo — is a dramatic treatment effect. The 54% complete diplopia resolution rate in patients who had diplopia at baseline is particularly notable: more than half of patients with double vision resolved it completely within 15 weeks of treatment.

The rapid onset finding deserves specific attention. Statistical significance in proptosis reduction was achieved at week 3, after only a single infusion. This speed of response is faster than what was observed in the teprotumumab clinical trials and has direct clinical significance: patients and clinicians can assess whether treatment is working within the first month rather than waiting for the full course to complete.

THRIVE-2: Phase 3 in chronic TED

THRIVE-2 (NCT06021054) used the same treatment design but enrolled adults with moderate-to-severe chronic TED, defined as disease onset more than 15 months before screening and proptosis at or above 3 mm with any CAS value. The mean time since TED onset in enrolled patients was 69.8 months — nearly 6 years — making this a population in whom fibrotic remodeling had been accumulating for a substantial period. The trial enrolled 188 patients (125 veligrotug; 63 placebo) with a 2:1 randomization.

Endpoint at week 15	Veligrotug	Placebo	p-value
Proptosis Responder Rate (PRR by Hertel)	56%	8%	p less than 0.0001
PRR by MRI/CT	48%	3%	p less than 0.0001
Mean proptosis reduction	2.34 mm	0.46 mm	p less than 0.0001
Overall Responder Rate	56%	7%	p less than 0.0001
Diplopia improvement (Gorman scale; in patients with diplopia at baseline)	56%	25%	p=0.0006
Diplopia complete resolution (Gorman scale)	32%	14%	p=0.0152
CAS of 0 or 1 achieved (patients with CAS at or above 3 at baseline)	54%	24%	p=0.0060
PRR statistically significant from week 3 (after 1 infusion)	Yes	—	—

Source: Endocrine Practice THRIVE-2 publication. 2025. doi:10.1016/j.eprac.2025. NCT06021054.

THRIVE-2 is the first randomized controlled trial in chronic TED to demonstrate statistically significant improvement in both proptosis and diplopia. The finding that 56% of chronic TED patients achieved a proptosis response, in a disease phase previously considered refractory to systemic pharmacotherapy, challenges the historical assumption that fibrotic TED could only be addressed surgically.

The 32% complete diplopia resolution rate in chronic TED patients with diplopia is also clinically significant: for a patient who has had double vision for years, the possibility of complete resolution from a 12-week course of infusions represents a meaningful departure from the trajectory that orbital decompression, strabismus surgery, and eyelid surgery were previously the only path toward.

---

How Lumvoa Compares to Tepezza: A Clinical Summary

Teprotumumab (Tepezza) was the first drug ever approved for TED and established proof of concept for IGF-1R inhibition in this disease. Lumvoa enters the same mechanistic space with several clinically meaningful differences.

Feature	Lumvoa (veligrotug)	Tepezza (teprotumumab)
Mechanism	Full IGF-1R antagonist	Partial agonist-antagonist at IGF-1R
Active TED data	Yes (THRIVE Phase 3)	Yes (pivotal Phase 2 and Phase 3)
Chronic TED data	Yes (THRIVE-2 Phase 3; first RCT in chronic TED with positive diplopia data)	Limited; label primarily supported by active TED data
Number of infusions	5 infusions over 12 weeks	8 infusions over 21 weeks
Dose	10 mg/kg IV every 3 weeks	10 mg/kg first infusion, then 20 mg/kg every 3 weeks
Onset of proptosis response	Week 3 (after 1 infusion)	Week 6 (after 2 infusions)
Hyperglycemia rate	Approximately 12%	Approximately 10%
Hearing impairment	Reported (class risk; approximately 16% in THRIVE active TED)	Reported (class risk; approximately 10 to 29% in trials)
Chronic TED diplopia resolution	32% complete resolution (THRIVE-2)	Not established in a dedicated chronic TED Phase 3 RCT

Sources: Viridian THRIVE/THRIVE-2 data; Tepezza FDA approval and prescribing information.

The most clinically significant difference for prescribers is the combination of fewer infusions and the chronic TED data. From a patient experience standpoint, 5 infusions over 12 weeks is a substantially lighter treatment burden than 8 infusions over 21 weeks. Infusion center visits for a condition that already carries significant quality-of-life burden matter.

Dr. Michael Yen, MD, Professor of Oculoplastic Surgery and Ophthalmology at Baylor College of Medicine and an investigator in the THRIVE program, noted that the clinical data demonstrated meaningful improvements across the full spectrum of TED, including rapid reductions in proptosis and significant improvements in diplopia, in both the active and chronic disease settings.

An important note on indirect comparison: THRIVE and THRIVE-2 were not head-to-head trials against teprotumumab. The efficacy numbers from Lumvoa’s trials should not be used for direct numeric comparison against teprotumumab’s trials. Patient populations, trial designs, and baseline characteristics differed across programs. What can be said is that both drugs demonstrated substantial, statistically significant, clinically meaningful benefits in their respective trials, and that Lumvoa now adds a Phase 3 evidence base in chronic TED where Tepezza’s regulatory support was limited.

---

Safety: What Prescribers and Patients Need to Know

Lumvoa’s safety profile is consistent with the IGF-1R inhibitor class established by teprotumumab, with some differences in rate and pattern across specific adverse events.

Most common adverse reactions (occurring in 5% or more of patients):

Muscle spasms were the most common adverse event overall, reported in approximately 36% of veligrotug-treated patients versus 6% of placebo patients in THRIVE-2. While striking in relative frequency, the muscle spasms were predominantly mild in severity and rarely led to treatment discontinuation. Other common adverse reactions include headache, fatigue, diarrhea, nausea, nasopharyngitis, elevated creatine phosphokinase, dry skin, and hypertension.

Key warnings and precautions:

Infusion reactions: Infusion-related reactions occurred in approximately 9% of Lumvoa-treated patients in the THRIVE program. Most were mild to moderate. Premedication before infusions and clinical monitoring during administration are standard management. Patients should be observed during and after each infusion.

Hyperglycemia: Hyperglycemia was reported in approximately 12% of veligrotug-treated patients, including patients without pre-existing diabetes. IGF-1R inhibition affects insulin signaling, and glucose elevation is a class effect shared with teprotumumab. Blood glucose should be monitored before and during treatment, particularly in patients with diabetes or prediabetes. Dose modification or antidiabetic medication adjustment may be required.

Hearing impairment: Hearing impairment, including potentially permanent hearing loss, is identified as a risk in Lumvoa’s prescribing information. This is a class effect of IGF-1R inhibitors in TED. In the THRIVE trials, hearing-related adverse events were reported in approximately 13% to 16% of veligrotug-treated patients in the active and chronic TED trials, with a placebo-adjusted rate of approximately 9.6% in THRIVE-2. Patients should be counseled about this risk before treatment initiation. Audiologic evaluation before and during treatment is clinically appropriate, and patients should report any new hearing changes promptly.

Inflammatory bowel disease: The prescribing information includes a risk of inflammatory bowel disease exacerbation. Patients with a history of inflammatory bowel disease should be evaluated carefully before initiating Lumvoa.

Embryo-fetal toxicity: Based on its mechanism of action affecting IGF-1R signaling, Lumvoa may cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for a specified period after the final infusion. Pregnancy testing before initiating treatment is appropriate.

Serious adverse events: Serious treatment-emergent adverse events in THRIVE were reported in 4 veligrotug-treated patients, all assessed as unrelated to treatment. Serious adverse events in THRIVE-2 occurred in 2% of veligrotug patients versus 3% of placebo patients. Treatment completion rates were high: 94% of veligrotug-treated patients in THRIVE-2 completed their full treatment course, a retention rate that speaks to the overall tolerability of the regimen.

---

What This Means for Patients and Clinicians

For patients with active TED

Lumvoa provides a second approved systemic pharmacologic option for active TED, alongside teprotumumab. The clinical discussion with an ophthalmologist or oculoplastic surgeon experienced in TED should now include both options, weighing the specific clinical profile, the shorter infusion course, the full antagonist mechanism, and individual patient factors including diabetes status, hearing risk, and infusion access.

For patients who have previously received teprotumumab and experienced disease recurrence or inadequate response, Lumvoa’s distinct pharmacological profile as a full antagonist represents a mechanistically differentiated alternative. Whether prior IGF-1R therapy exposure affects veligrotug response is a question that ongoing clinical experience will address. The THRIVE trials excluded patients who had received prior anti-IGF-1R therapy, so the evidence in this subgroup is not yet established.

For patients with chronic TED

This is the population for whom Lumvoa’s approval is most transformative. Until now, patients in the chronic phase of TED with established proptosis and fixed diplopia faced a choice between living with these manifestations or pursuing surgical correction: orbital decompression for proptosis, strabismus surgery for diplopia, and eyelid surgery for cosmetic and functional restoration. These surgeries are effective but carry their own risks and often require sequential procedures.

The THRIVE-2 data demonstrates that pharmacologic reversal of chronic TED manifestations is achievable in a meaningful proportion of patients. A 56% proptosis response rate and 32% complete diplopia resolution in a population with a mean TED onset of nearly 6 years challenges the assumption that fibrotic orbital changes are irreversible. For patients and clinicians managing chronic TED, a conversation about whether a 12-week course of Lumvoa infusions might reduce or eliminate the need for surgical intervention is now evidence-supported.

Christine Gustafson, Founder and Executive Director of the TED Community Organization, noted that a new treatment option could benefit many patients living with the physical and emotional burden of thyroid eye disease. The psychosocial burden of TED is well-documented: disfiguring proptosis, double vision that impairs independence, and pain with eye movement contribute to depression, social withdrawal, and reduced quality of life that persist well beyond the active inflammatory phase.

Practical access and administration

Lumvoa launched commercially on June 26, 2026, the same day as FDA approval. Treatment requires intravenous infusion access, which means a certified infusion center or hospital outpatient setting. The 5-infusion schedule over 12 weeks, with infusions every 3 weeks, represents a meaningful reduction in infusion center visits compared to teprotumumab’s 8-infusion protocol. Viridian has established a patient support program to assist with access, insurance navigation, and infusion site coordination.

For related HED coverage on autoimmune and rare endocrine conditions, see our post on Tzield (teplizumab) approved as the first disease-modifying therapy for recently diagnosed Stage 3 type 1 diabetes and our post on Hympavzi (marstacimab) expanding to cover children aged 6 to 11 and inhibitor-positive hemophilia patients.

---

Sources

Viridian FDA approval press release: Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease. BusinessWire. June 26, 2026.

Eyewire clinical summary: FDA Approves Viridian’s Lumvoa for Thyroid Eye Disease. eyewire.news. June 2026.

Pharmacally detailed clinical coverage: FDA Approves Veligrotug as First Treatment for Active and Chronic Thyroid Eye Disease. pharmacally.com. June 2026.

Ophthalmology Times (full safety and mechanism detail): FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages. ophthalmologytimes.com. June 2026.

Optometry Times: FDA approves Lumvoa (veligrotug-vvze) for active and chronic thyroid eye disease. optometrytimes.com. June 2026.

HCPLive BLA acceptance coverage: FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease. hcplive.com. March 2026.

THRIVE topline results (Endocrine Practice): Efficacy and Safety of Veligrotug, a Full Antagonist Monoclonal Antibody to IGF-1 Receptor, in Active Thyroid Eye Disease: THRIVE Phase 3 Topline Results. Endocrine Practice. 2025.

THRIVE PMC abstract: OR31-04 Efficacy and Safety of Veligrotug in Active TED: THRIVE Phase 3 Topline Results. PMC12545473.

THRIVE-2 primary results (Endocrine Practice): THRIVE-2 Phase 3 Trial of Veligrotug in Chronic Thyroid Eye Disease: Efficacy and Safety at 15 Weeks. Endocrine Practice. 2025.

THRIVE-2 topline press release (Viridian): Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial. ir.viridiantherapeutics.com. 2024.

THRIVE trial registration: NCT05176639. ClinicalTrials.gov.

THRIVE-2 trial registration: NCT06021054. ClinicalTrials.gov.

Viridian BLA acceptance and Priority Review: Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug. ir.viridiantherapeutics.com. 2025.

Teprotumumab FDA approval: FDA approves teprotumumab-trbw for thyroid eye disease. FDA.gov. January 2020.

IGF-1R biology: IGF-1R in autoimmune disease. PMC6126283.

Thyroid eye disease overview: Thyroid Eye Disease. StatPearls. NCBI.

Graves disease overview: Graves Disease. NIDDK.

Lumvoa prescribing information: LUMVOA (veligrotug-vvze) Prescribing Information. Viridian Therapeutics. 2026.

Patient resources: TED Community Organization | American Thyroid Association: TED patient resources | Viridian Lumvoa patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Thyroid eye disease management, including the decision to initiate pharmacologic therapy with Lumvoa or Tepezza, requires individualized evaluation by a board-certified ophthalmologist, oculoplastic surgeon, or endocrinologist with experience in TED. Patients with active or chronic TED should discuss all systemic treatment options with their managing specialist before initiating therapy.

The essentials: On June 16, 2026, the FDA approved Rextovy (naloxone hydrochloride 4 mg nasal spray, Amphastar Pharmaceuticals) for over-the-counter sale, making it the third naloxone nasal spray available without a prescription in the United States. No prescription, no pharmacist consultation, and no physician visit is required. Consumers can purchase Rextovy directly at pharmacies, convenience stores, and online retailers. What it is: a single 4 mg intranasal spray per device, supplied in a carton of 2 devices. The same active ingredient and the same 4 mg dose as OTC Narcan (Emergent BioSolutions). The difference is manufacturer: Rextovy is made by Amphastar Pharmaceuticals. A third OTC product, RiVive (Harm Reduction Therapeutics), contains 3 mg. All three are approved for bystander use without medical training. Rx version pricing: approximately $44 to $60 per box. OTC pricing was not immediately available at launch. Historical precedent: OTC naloxone prices declined by only approximately $0.49 per quarter between late 2023 and late 2024 following the first OTC approval, according to a 2026 study in the Journal of Substance Use and Addiction Treatment. A third competitor changes the economic calculus. Overdose death trend: in the 12-month period ending August 2023, 111,451 overdose deaths were reported; in the 12-month period ending December 2025, 68,632 were reported — a 38% decline since the first OTC naloxone approval. Drug overdose deaths remain a major public health issue, primarily driven by synthetic opioids including illicit fentanyl. Pricing equity note: the same 2026 study found that areas with larger American Indian and Alaska Native populations paid an estimated more than $5 extra per unit compared with predominantly white communities — a documented racial pricing disparity in OTC naloxone access.

The number of overdose deaths has dramatically decreased since the first FDA approval of an OTC naloxone nasal spray in 2023, but drug overdose persists as a major public health issue in the U.S., primarily driven by synthetic opioids like illicit fentanyl. In the 12-month period ending August 2023, 111,451 overdose deaths were reported. In the 12-month period ending December 2025, 68,632 were reported. That 38% decline is meaningful, and OTC naloxone availability is widely credited as one of its contributors. It is also not enough. More than 68,000 people dying per year from overdose is not a public health success. It is a reduced catastrophe. BioSpace

Against that backdrop, the FDA’s June 16, 2026 approval of Rextovy (naloxone hydrochloride, Amphastar Pharmaceuticals) as the third OTC naloxone nasal spray matters for two distinct reasons. The first is access: more manufacturers, more retail channels, and more products on shelves means more opportunities for the right person to have the right medication at the right moment. The second is economics: the most persistent barrier to naloxone adoption since the first OTC approval has not been awareness. It has been price. A third competitor in a market where prices have barely moved creates conditions for the competition that could finally change that.

This post covers what naloxone is and how it works, the OTC naloxone landscape and how Rextovy fits into it, what the pricing and access research actually shows, what the evidence says about bystander naloxone and its effect on survival, and what any person reading this needs to know about how to use it.

---

What Opioid Overdose Is and Why Minutes Matter

Opioid overdose occurs when the concentration of opioids in the body exceeds what the brain’s opioid receptors can manage without suppressing essential automatic functions. Opioids bind to mu-opioid receptors in the brainstem’s respiratory control centers. At therapeutic doses, this produces analgesia and sedation. At overdose doses, it produces profound respiratory depression: breathing slows, becomes shallow, and eventually stops. Without intervention, hypoxia progresses to cardiac arrest and death, typically within minutes.

The trajectory of a fatal opioid overdose, from respiratory depression to death, unfolds in a window of approximately 1 to 5 minutes in many cases, faster with high-potency synthetic opioids like fentanyl and carfentanil, somewhat longer with longer-acting opioids like methadone. This time window is the entire clinical rationale for OTC naloxone: by the time emergency medical services arrive, a reversible overdose has often become an irreversible one.

Recognizing an opioid overdose requires recognizing several characteristic signs. Any person who is:

• Unresponsive or cannot be woken up
• Breathing slowly, shallowly, or not at all
• Making gurgling, choking, or rattling sounds (sometimes called the “death rattle”)
• Limp and unable to hold their head up
• Showing blue, gray, or pale lips, gums, or fingertips (indicating hypoxia)
• Showing pinpoint (very small) pupils

should be treated as a suspected opioid overdose. Naloxone will not harm someone who does not have opioids in their system, so the risk of administering it to someone who turns out not to be overdosing on opioids is negligible. The risk of not administering it to someone who is overdosing on opioids is death.

---

How Naloxone Works: The Mechanism

Naloxone is a competitive opioid receptor antagonist. It binds to the same mu-, kappa-, and delta-opioid receptors in the brain that opioids bind to, but it does not activate them. Because naloxone’s binding affinity for these receptors is higher than that of most opioids, it rapidly displaces the opioid molecules already occupying the receptors and occupies those sites itself, blocking further opioid activity.

The clinical result of this receptor displacement is the reversal of opioid-induced respiratory depression within 2 to 5 minutes of administration. The person begins breathing again. Consciousness typically returns. The overdose reversal is complete for the duration of naloxone’s action.

The critical pharmacokinetic limitation of naloxone is its shorter duration of action compared to most opioids. Naloxone’s effects last approximately 30 to 90 minutes. Many opioids, particularly long-acting formulations like extended-release oxycodone or methadone, last substantially longer. Illicit fentanyl, which is now the dominant driver of overdose deaths, acts rapidly but can linger at high receptor occupancy.

This means that after naloxone wears off, opioid effects can return, a phenomenon called re-narcotization. This is the clinical reason why calling 911 after the first dose is not optional, even if the person wakes up and feels better. The naloxone reversal is temporary. The opioids are still in the system. Without professional medical monitoring and potentially additional doses, re-narcotization can cause a second respiratory depression episode just as lethal as the first.

What happens when the person wakes up is also important for bystanders to understand. Naloxone precipitates acute opioid withdrawal in opioid-dependent individuals by abruptly displacing opioids from receptors throughout the body. This produces sudden withdrawal symptoms: sweating, shaking, nausea, vomiting, irritability, and sometimes agitation or aggression. This is a normal and expected physiological response, not a sign that something has gone wrong. It is not dangerous. The person may be confused and frightened. The appropriate response is calm reassurance and staying with them until emergency services arrive.

Naloxone does not cause a “high” or produce any opioid effect In people who do not have opioids in their system, naloxone produces no clinically significant effect. It is pharmacologically inert as a monotherapy: it blocks receptors but does not activate them, so administering it to someone who is not overdosing on opioids produces no harm. This is one reason the FDA and public health authorities consistently recommend a low threshold for use: when in doubt, administer it. The consequence of a false positive is negligible. The consequence of a false negative is death.

---

The OTC Naloxone Landscape: Where Rextovy Fits

The United States OTC naloxone nasal spray market now has three approved products:

Product	Manufacturer	Dose	OTC approval	Status
Narcan 4 mg	Emergent BioSolutions	4 mg per spray	March 2023	Commercially available
RiVive 3 mg	Harm Reduction Therapeutics (nonprofit)	3 mg per spray	July 2023	Commercially available
Rextovy 4 mg	Amphastar Pharmaceuticals	4 mg per spray	June 16, 2026	Newly approved

Rextovy contains the same active ingredient at the same dose as OTC Narcan. The products are pharmacologically equivalent: both deliver 4 mg of naloxone hydrochloride as a single intranasal spray. The distinction is manufacturer, supply chain, and ultimately price. Amphastar Pharmaceuticals is a well-established injectable and inhalable drug manufacturer with existing manufacturing infrastructure for drug products in similar delivery formats. Its entry into the OTC naloxone market adds a second 4 mg option and a new supply source.

The original prescription version of Rextovy was approved on March 7, 2023. The June 16, 2026 action is a labeling revision converting that product to OTC status, the same regulatory pathway used for OTC Narcan in 2023.

---

How to Use Rextovy: Step-by-Step

Rextovy’s packaging includes pictorial step-by-step instructions designed for use without medical training. The FDA-approved dosing protocol:

Step 1: Call 911 immediately after (or simultaneously with) giving the first dose. Do not wait to see if the dose works before calling. Emergency services need to be on the way regardless of how quickly the person responds.

Step 2: Lay the person on their back. Tilt their head back slightly to open the airway.

Step 3: Insert the tip of the nasal spray device gently into one nostril. Press the plunger firmly to deliver the full 4 mg dose as a single spray.

Step 4: Wait 2 minutes and watch for a response: spontaneous breathing, return of consciousness, movement.

Step 5: If there is no response after 2 minutes, administer the second device into the opposite nostril. The carton contains 2 devices for this reason.

After administration: Stay with the person until emergency services arrive. If the person regains consciousness, keep them calm and prevent them from taking more opioids. Explain that medical help is coming. If they become agitated (from naloxone-precipitated withdrawal), do not leave. If they lose consciousness again after initial recovery, administer the second dose if not already used and continue rescue breathing if trained to do so.

Rescue breathing: If you know rescue breathing or CPR, administer it while waiting for naloxone to take effect and after doses are given. Rescue breathing can maintain oxygenation during the reversal window.

The fentanyl consideration: Illicit fentanyl and its analogues are significantly more potent than heroin or prescription opioids and may require higher or repeat naloxone doses to achieve reversal. A single 4 mg dose may not be sufficient in a high-potency fentanyl overdose. This is why the 2-device carton is important, and why calling 911 is critical: emergency responders carry additional naloxone doses.

---

The Pricing Problem and Why a Third Competitor Matters

The clinical and public health value of OTC naloxone is not theoretical. Bystander administration of naloxone before emergency services arrive is associated with substantially higher survival rates in observed overdose events. Multiple studies across community overdose prevention programs consistently show that having naloxone present at the scene and having someone willing and able to use it is one of the most effective single interventions for preventing overdose death.

The problem is access, and access in this context is inseparable from price.

A 2026 study published in the Journal of Substance Use and Addiction Treatment found that OTC Narcan prices declined by only approximately $0.49 per quarter between late 2023 and late 2024, a period during which total sales actually fell slightly. The study also identified a documented racial pricing disparity: areas with larger American Indian and Alaska Native populations paid an estimated more than $5 extra per unit compared with predominantly white communities.

The prescription version of Rextovy currently sells at approximately $44 to $60 per two-dose carton, which is the same general price range as prescription Narcan. OTC pricing was not immediately disclosed at Rextovy’s launch. The meaningful question is not the launch price but the trajectory: with three manufacturers in the OTC naloxone market rather than two, and with Amphastar’s manufacturing cost structure potentially different from Emergent BioSolutions, there is now a realistic competitive mechanism that did not previously exist.

The FDA has stated explicitly that the availability of multiple approved formulations expands access and market availability, encourages competition that may reduce cost, and offers alternative sourcing options. That is a policy statement, not a guarantee. But the mechanism is sound: competition-driven price reduction in generic and OTC pharmaceutical markets follows predictable patterns, and the OTC naloxone market has been waiting for it.

For the communities with the highest overdose burden — uninsured populations, communities with high rates of opioid use disorder, and the communities of color documented to face pricing disparities — even a meaningful reduction from the current $44 to $60 per box baseline could translate directly into lives saved.

---

Naloxone Is Safe to Give — and There Are No Situations Where Hesitation Is the Right Choice

This point is worth stating plainly because hesitation at the scene of a suspected overdose remains one of the most documented barriers to naloxone use.

Naloxone will not harm someone who does not have opioids in their system. It is not possible to give a fatal dose of naloxone to an overdose victim. The drug has no significant pharmacological activity in the absence of opioid receptor occupancy. Bystanders who are uncertain whether someone is overdosing on opioids should administer naloxone anyway: if opioids are not present, the spray produces no effect. If opioids are present, it may save their life.

The withdrawal symptoms that naloxone can precipitate — agitation, sweating, nausea, vomiting — are distressing but not medically dangerous. They are significantly preferable to continued opioid-induced respiratory depression. A person who is angry and nauseous after naloxone administration is alive. That is the outcome.

SAMHSA’s opioid overdose prevention guidance is clear: treat first, call for help, stay present. There is no scenario in which waiting to see whether a suspected overdose resolves on its own is the appropriate response.

---

What This Means Practically

If you live with or care for someone using prescription opioids: Ask your pharmacist about keeping naloxone at home. Prescription opioid use, including opioids prescribed legitimately for chronic pain, carries overdose risk — particularly in higher doses, in combination with other sedating medications, or in patients with sleep apnea. Having naloxone in the home is increasingly recommended as a standard safety precaution alongside prescription opioid therapy.

If you use opioids yourself: Carry naloxone. Tell a trusted person where it is and how to use it. The person most likely to administer naloxone in an opioid-related emergency is someone in the immediate vicinity, not a first responder.

If you work in any setting where opioid use may occur: Workplaces, schools, community organizations, faith communities, and public venues are all settings where overdoses occur and where having naloxone present changes outcomes. Rextovy joining the OTC market means one more product on more shelves at potentially lower cost. Stock it.

If you are a pharmacist or healthcare provider: SAMHSA and the CDC recommend co-prescribing naloxone with opioid prescriptions, particularly at higher doses. The OTC availability of Rextovy, Narcan, and RiVive means that the conversation about naloxone access can now happen in any setting — a pharmacy counter, a community health worker visit, a school nurse office — without requiring a prescription. Patient education about signs of overdose, how to use the spray, and why calling 911 is non-negotiable after the first dose saves lives.

For related HED coverage on the opioid crisis treatment landscape, see our post on the FDA’s approval of Sublocade (buprenorphine extended-release injection) for opioid use disorder and our coverage of how the Great American Recovery Initiative has shaped FDA drug approvals and substance use disorder policy in 2026.

If you or someone you know is struggling with opioid use disorder, contact the SAMHSA National Helpline at 1-800-662-4357 (free, confidential, 24/7) or visit findtreatment.gov.

---

Sources

FDA approval announcement: FDA broadens access to over-the-counter naloxone nasal spray for opioid overdose. FDA.gov. June 16, 2026. BioSpace

Drugs.com approval news: FDA Approves Rextovy (naloxone hydrochloride) Nasal Spray for Over-the-Counter Use. drugs.com. June 16, 2026.

Dermatology Advisor clinical summary (with dosing and packaging): Over-the-Counter Rextovy Cleared for Opioid Overdose Treatment. dermatologyadvisor.com. June 2026.

Drug Topics coverage (with pricing research and pharmacist comment): The FDA Approves Rextovy, an OTC Naloxone for Opioid Overdose. drugtopics.com. June 2026.

TechTimes (OTC market analysis with pricing study detail): Naloxone Nasal Spray Gets Third OTC Brand as FDA Approves Rextovy by Amphastar. techtimes.com. June 2026.

The Hill news coverage: FDA approves third over-the-counter opioid overdose nasal spray. thehill.com. June 2026.

Psychiatry Advisor clinical summary: Over-the-Counter Rextovy Cleared for Opioid Overdose Treatment. psychiatryadvisor.com. June 2026.

Rextovy original Rx approval (March 2023): Rextovy FDA Approval History. drugs.com.

Narcan OTC approval (March 2023): FDA approves first nonprescription naloxone nasal spray. FDA.gov.

Rextovy prescribing information: Rextovy (naloxone hydrochloride) Package Insert. Amphastar Pharmaceuticals. 2026.

Naloxone mechanism and overdose StatPearls: Opioid Toxicity. StatPearls. NCBI.

Mu-opioid receptor pharmacology: Opioid Receptors. StatPearls. NCBI.

Bystander naloxone and survival outcomes: Bystander Naloxone Administration and Opioid Overdose Outcomes. PMC9388745.

CDC naloxone consumer guidance: Naloxone for Opioid Overdose. CDC.

SAMHSA opioid overdose guidance: Opioid Overdose Prevention. SAMHSA.

SAMHSA National Helpline: SAMHSA National Helpline. 1-800-662-4357.

Find treatment: findtreatment.gov. SAMHSA.

Patient resources: National Alliance for Eating Disorders Helpline: 1-866-662-1235 (removed — not relevant to this post) | 988 Suicide and Crisis Lifeline: call or text 988 | SAMHSA National Helpline: 1-800-662-4357 | Harm Reduction Coalition | Next Distro (mail-based naloxone access)

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Rextovy is an over-the-counter emergency medication for suspected opioid overdose. Administering naloxone does not replace calling 911: emergency medical services must be contacted immediately after any suspected overdose. Naloxone is a temporary reversal agent; professional medical evaluation and monitoring are required after administration. If you or someone you know is struggling with opioid use disorder, call the SAMHSA National Helpline at 1-800-662-4357.